Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 Magnaquest, ... video, data and cloud computing operators has signed ... pharma giant for Internet of Things (IoT) related ... offered on subscription model.      (Logo: ... is striving for business innovations to make healthcare ...
(Date:7/30/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $453.1 million, a 9 percent increase ... 17 percent increase on a constant currency basis).  Net ... June 30, 2014.  Diluted earnings per share for the ... 30, 2014.  The results for the ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... a privately held personalized medicine company focused on cancer, ... C (GCC) Lymph Nodes (LN) Classification as a Prognostic ... Pooled Analysis" at the 2012 American Society of Clinical ... 21, 2012.  The data from the paper demonstrate the ...
... 23, 2012 InspireMD, Inc. (OTC BB: NSPR) (the ... the development and commercialization of its proprietary stent platform ... today announced its business objectives for 2012 and reviewed ... the Company,s proprietary MicroNet™ platform technology. ...
Cached Medicine Technology:Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer 2InspireMD Provides Corporate Update, Plans for 2012 2InspireMD Provides Corporate Update, Plans for 2012 3InspireMD Provides Corporate Update, Plans for 2012 4InspireMD Provides Corporate Update, Plans for 2012 5InspireMD Provides Corporate Update, Plans for 2012 6
(Date:8/3/2015)... Miami, Florida (PRWEB) , ... August 03, 2015 , ... ... neuropathy pain accompanied by tissue injury caused by diabetes after many years of suffering ... work many times, and he didn’t want to ask for extra time off or ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that hopes ... G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem cell ... Hospital and in the UofL Department of Pediatrics . Patients are currently ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather Pugh ... of care for patients at this natural health care center in Winamac. , "Oftentimes ... Heal said. "Heather's role is vital to our approach because we want to focus ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are ... and women often causing pain and discomfort. Those who spend a lot of time ... Northeast Houston Vein Center is doing what it can to create awareness and provide ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3
... ... expensive education in the thriving nursing industry. , ... Seattle, Washington (PRWEB) July 30, 2009 -- According to ... and online nursing degrees are becoming a popular and effective way to capitalize on ...
... with the autoimmune disease systemic lupus erythematosus (SLE) have ... in their immune responses and treatment with immunosuppressive drugs. ... in immunocompromised patients, it is recommended that patients with ... do not increase disease activity. Both antibody and cell-mediated ...
... , , TAMPA, Fla., July 29 ... great excitement and enthusiasm that Tampa Bay Radiation Oncology announces the grand ... 2009. Located at 12206 Bruce B Downs Blvd, near the VA ... to residents in the Tampa Bay area communities. , , ...
... , , ... a beautiful place for patients to relax, it is an award ... Agnes and Morland Hamilton Healing Conservatory at Aurora St. Luke,s Medical ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) , ...
... OF PRUSSIA, Pa., July 29 Health Market Science ... product for the master data management market. The ... including life sciences, payer, pharmacy benefits management and pharmacy. ... for complete customer master data management. , ...
... , ADDISON, Texas, July 29, ULURU Inc. ... and best clinical practice will be demonstrated in a hands-on Wound Care ... August 2. In addition, clinical evidence on the treatment of wounds ... meeting. , , Renaat Van den Hooff, President and ...
Cached Medicine News:Health News:All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 2Health News:Immune responses to flu vaccine are diminished in lupus patients 2Health News:Aurora St. Luke's Healing Garden Earns LEED Certification 2Health News:Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market 2Health News:Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market 3Health News:ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada 2Health News:ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: